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Differentiation therapy has been proposed as a new
approach to selectively engage the process of tumor
cell differentiation during chemotherapy of cancer.
Our recent in vitro study suggests that such an ap-
proach can be extended and utilized for the selection
of tumor-derived insulin-producing cells for trans-
plantation. Repeated treatment with streptozotocin
selected toxin resistant subpopulation of insulin
producing tumor RINmS cells, characterized by
increased level of insulin content and secretion. In
the present study RINmS cells were found to have
higher glucose sensitivity and insulin response com-
pared with parental RINm cells. In addition, com-
pounds known to induce elevated level of cAMP in
beta-cells, such as isobutyl methyl xanthine, and
forskolin, potentiated glucose-induced insulin se-
cretion of RINmS, but had no effect on the naive
parental RINm cells. These experiments suggest that
differentiation therapy can be utilized for engineer-
ing insulin producing cells with improved defense
and secretory mechanisms.
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INTRODUCTION
Tumor derived insulin-producing beta-cell lines
constitute a potential source for islet transplan-
tation. E1’21 To achieve long-term functioning,
transplanted beta cells must posses a high level
of differentiation to allow adequate glucose
sensing, insulin processing and secretion, and
an effective defense mechanism.
Recently, differentiation therapy has been
proposed as a new approach to selectively
engage the process of tumor cell differentiation
during chemotherapy of cancer. E3J According
to this approach, cytotoxic agents, including
chemical compounds and cytokines used in can-
cer therapy, can induce drug resistance, but in
certain conditions, can also lead to elimination of
tumorigenic cells and to recovery of normal cell
homeostasis. [4-6]
We have recently found that repeated, in vitro
treatment, with streptozotocin (STZ), an anti-
neoplasticcompound utilized for the treatment of
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patients with insulinoma, selects toxin resistant
subpopulation of insulin-producing RINmS tu-
mor cells. [7,s] The higher resistance to both STZ
and alloxan (AL), was found to be at least par-
tially dependent on the lower expression of the
glucose transporter 2 (GLUT-2) in the selected
cells. Despite the lower expression of GLUT-2
in the resistant cells, their functional capacity,
reflected by the increased intracellular insulin
content and insulin release, did not seem to be
impaired. In the present study we further evalu-
ated the insulin response to different secretago-
gues, and used the proliferation capacity of
RINmS cells as a marker of differentiation stage.
METHODS
Cell Culture and Selection Procedure
The RINm cells, which have been previously
described in detail,
[9] were cultured in RPMI
1640 medium, supplemented with 10% FCS,
2mmol/1 L-glutamine, 100 IU penicillin and
100tg/ml streptomycin. Cells were grown in
plastic tissue culture flasks at 37C in 95%
humidified air with 5% CO2. The toxin resistant
cells (RINmS) were developed by exposing cells
to 10mM of STZ in 2 passages, as previously de-
scribed. [8 Parallel cultures of untreated RINm
cells were used as controls. The cells (passages
14-22), free of micoplasma contamination, were
used in all experiments.
Insulin Response to Increasing Glucose
Concentrations and Effect of IBMX
and FSK on Insulin Release
Prior to the experiments (72 h), 2 x 105 cells/well
were seeded in 24-well plates. After washing,
cells were preincubated for I h in glucose-free
Krebs-Ringer bicarbonate buffer (KRB) and re-
incubated in the buffer at 37C for additional
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FIGURE Glucose-induced insulin secretion from RINm and RINmS cells. Effect of various glucose concentrations was
assessed over a I h incubation period at 37C. The level of insulin was estimated by radioimmunoassay. Values are mean 4- SE
from 4 independent experiments. *p < 0.05 compared with basal secretion (0mM of glucose).TUMOR-DERIVED INSULIN-PRODUCING CELLS 235
hour with various secretagogues: glucose 5 and
15mM; isobutyl methyl xanthine (IBMX)
0.1 mM; forskolin (FSK) 1 tM. The level of basal
insulin secretion into KRB was evaluated in the
absence of secretagogues. Supernatants were
centrifuged and collected for insulin determina-
tion by RIA.
Insulin Radioimmunoassay
The insulin content was determined by RIA
using a rat insulin standard. Samples were
thawed and centrifuged prior to insulin
determination.
Cell Growth Characteristics
Cells were seeded into 24-well plates in culture
medium at a cell density of 2x 105/well.
Following trypsinization, the cell number per
well was determined under a light microscope
in a counting chamber at 2,3, 6 and 8 days after
seeding.
Statistical Analysis
Analysis of variance (ANOVA) was utilized for
evaluation of the statistical significance of differ-
ences between groups. Results are presented as
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FIGURE 2 Insulin secretion from RINm (A) and RINmS (B) cells in response to glucose and IBMX or FSK. Three days before
incubation. 4 x 105 cells/well were seeded in 12-well plates. After two washes, cells were preincubated for 60min in glucose-
free buffer and incubated for another 60min in the same buffer containing the various additions (glucose 0mM, 5mM; IBMX
0.1 mM; FSK pM). The results represent the mean of 4 separate experiments. *p < 0.05 compared with RINm cells under the
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mean values 4-SEM of 3-4 independent, re-
peated experiments. Experiments were per-
formed in triplicate; p <0.05 was considered
significant.
RESULTS AND DISCUSSION
We previously demonstrated that repeated ex-
posure of tumor-derived insulin-producing
RINm cells to high doses of STZ leads to se-
lection of a cell subpopulation (RINmS) with a
higher resistance not only to STZ, but also to
AL. I7,s] The higher cell defense property of the
surviving cells was found to be associated with a
decreased expression of GLUT-2, which acts as a
transporter of STZ and AL. In addition to their
modified defense potential, resistant RINmS
cells were found also to contain and release
significantly higher level of insulin when com-
pared with their untreated parental RINm cells.
The finding of low GLUT-2 expression in the
highly resistant and more differentiated RINmS
cells is unexpected and opposes that of high
level of GLUT-2 and extreme cell sensitivity
to diabetogenic toxins reported in experiments
with rodent islets. Such controversy could result
from the different cell pathways of natural
selection in the whole animals, and the artifi-
cially-induced in vitro selection of RINmS cells.
We further evaluated the cell functional
capacity and found that RINmS cells are more
sensitive to increasing concentrations of glucose
when compared with RINm cells. Thus, incuba-
tion with 5mM of glucose alone induced a
twofold increase in insulin secretion in RINmS
and had no effect in RINm cells (Fig. 1). Fur-
thermore, IBMX and FSK, compounds which
induce elevation of cAMP level in beta-cells,
lead to a 4-fold increase of glucose (5mM)
induced insulin secretion in the toxin-resistant
RINmS but not in the parental cells (Fig. 2).
These data suggest that the lower GLUT-2 ex-
pression of RINmS cells, previously reported,
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FIGURE 3 Growth curves ofRINm (open circles) and RINmS (solid circles) cells expressed as number of cells per well at 2, 3, 6
and 8 days after seeding. Data are given as means 4- SEM from 3 independent experiments. *p < 0.05 compared with RINm
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is probably sufficient to maintain the mech-
anism of glucose induced insulin secretion. It
is possible that the higher cellular insulin con-
tent of RINmS cells, its improved regulation
and secretion is probably due to transition of
this cell population to a higher cell differentia-
tion stage. This possibility is further supported
by our finding of lower cell proliferative activity
in RINmS when compared with parental RINm
cells (Fig. 3). A similar induction of drug
resistance in association with cell differentia-
tion and growth suppression was previously
reported in selected tumor cells following anti-
neoplastic drug treatment. I3,5 Over-expression
of multi drug resistance genes (mdrl), and
decreased expression of nuclear transcription
factor genes (c-myc), which control tumorigenic
development are believed to be the underlying
molecular mechanisms which activate such cel-
lular pathway. Ilol We speculate that the alkylat-
ing agent STZ, not only induces resistance to
diabetogenic drugs, but also induces increased
DNA methylation, which in turn reinforces
differentiation process in selected cells.
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